Dutasteride tamsulosin

Results: 21



#Item
11U.S. Food and Drug Administration  Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only. This content has not been altered or updated since it was archived

U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only. This content has not been altered or updated since it was archived

Add to Reading List

Source URL: www.fda.gov

Language: English
12Best Buy Drugs Report on Drugs to Treat Enlarged Prostate

Best Buy Drugs Report on Drugs to Treat Enlarged Prostate

Add to Reading List

Source URL: consumerhealthchoices.org

Language: English - Date: 2013-07-06 14:31:50
13Recent Publications from Physicians at the Iris Cantor Men’s Health Center: Jamzadeh AE, Xie D, Laudano M, Seklehner S, Elterman DS, Shtromvaser L, Lee R, Kaplan SA, Te AE, and Chughtai B. Urodynamic characterization o

Recent Publications from Physicians at the Iris Cantor Men’s Health Center: Jamzadeh AE, Xie D, Laudano M, Seklehner S, Elterman DS, Shtromvaser L, Lee R, Kaplan SA, Te AE, and Chughtai B. Urodynamic characterization o

Add to Reading List

Source URL: nyp.org

Language: English - Date: 2013-08-08 10:44:37
14Microsoft Word - BPH Treatment Mar 10.doc

Microsoft Word - BPH Treatment Mar 10.doc

Add to Reading List

Source URL: www.oregon.gov

Language: English - Date: 2014-07-15 14:00:38
15Microsoft Word - Avodart_PM _2013-09-12_

Microsoft Word - Avodart_PM _2013-09-12_

Add to Reading List

Source URL: www.gsk.ca

Language: English - Date: 2013-09-23 16:01:05
16JALYN may signal the presence of prostate cancer and should be evaluated, even if those values are still within the normal range for untreated men. (5.3) 	 Do not use JALYN with strong inhibitors of cytochrome P450 (C

JALYN may signal the presence of prostate cancer and should be evaluated, even if those values are still within the normal range for untreated men. (5.3)  Do not use JALYN with strong inhibitors of cytochrome P450 (C

Add to Reading List

Source URL: www.accessdata.fda.gov

Language: English - Date: 2013-04-29 16:52:22
17	  HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use AVODART safely and effectively. See full prescribing information for AVODART.

 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use AVODART safely and effectively. See full prescribing information for AVODART.

Add to Reading List

Source URL: www.accessdata.fda.gov

Language: English - Date: 2013-05-01 16:59:55
18-------------------------------CONTRAINDICATIONS-----------------------•	 Pregnancy and women of childbearing potential. (4, 5.4, 8.1) •

-------------------------------CONTRAINDICATIONS-----------------------• Pregnancy and women of childbearing potential. (4, 5.4, 8.1) •

Add to Reading List

Source URL: www.accessdata.fda.gov

Language: English - Date: 2011-06-10 14:49:27
19CENTER FOR DRUG EVALUATION AND RESEARCH Approval Package for:

CENTER FOR DRUG EVALUATION AND RESEARCH Approval Package for:

Add to Reading List

Source URL: www.accessdata.fda.gov

Language: English - Date: 2011-02-03 14:44:20
20•	 Patients with previously demonstrated, clinically significant hypersensitivity (e.g., serious skin reactions, angioedema) to AVODART or other 5α-reductase inhibitors. (4)

• Patients with previously demonstrated, clinically significant hypersensitivity (e.g., serious skin reactions, angioedema) to AVODART or other 5α-reductase inhibitors. (4)

Add to Reading List

Source URL: www.accessdata.fda.gov

Language: English - Date: 2010-09-09 19:11:22